Unusual Symptoms

Lab Test Various Dr. JH Labcorp January 25, 2024


Test In Range Out Of Range Units Reference
CBC With Differential/Platelet        
WBC 4.2   x10E3/uL 3.4 - 10.8
RBC   L 3.76 x10E6/uL 4.14 - 5.80
Hemoglobin   L 12.2 g/dL 13.0 - 17.7
Hrmatocrit   L 36.5 % 37.5 - 51.0
 
97   fL 79 - 97
MCH 32.4   pg 26.6 - 33.0
MCHC 33.4   g/dL 31.5 - 35.7
RDW 11.8   % 11.6 - 15.4
Platelets 207   x10E3/uL 150 - 450
 
Neutrophils 55   %  
Lymphs 29   %  
Monpcytes 10   %  
Eos 4   %  
Basos 1   %  
 
Neutrophils (sbsolute) 2.4   x10E3/uL 1.4 - 7.0
Lymphs (absolute) 1.2   x10E3/uL 0.7 - 3.1
Monocytes (sbsolute) 0.4   x10E3/uL 0.1 - 0.9
Eos (absolute) 0.2   x10E3/uL 0.0 - 0.4
Baso (absolute) 0.0   x10E3/uL 0.0 - 0.2
 
Immature Granulocytes 1   %  
Immature Grans (Abs) 0.0   x10E3/uL 0.0 - 0.1
 
Comp. Metabolic Panel        
Glucose 97   mg/dL 70 - 99
 
BUN 21   mg/dL 8 - 27
Creatinine 1.01   mg/dL 0.76 - 1.27
eGFR 74   gt; 59 mL/min/1.73
BUN/Creatinine Ratio 21     10 - 24
Sodium 139   mmol/L 134 - 144
 
Potassium 4.5   mmol/L 3.5 - 5.2
Chloride 102   mmol/L 96 - 106
Carbon Dioxide, Total 25   mmol/L 20 - 29
Calcium 9.1   mg/dL 8.6 - 10.2
Protein, Total 6.3   g/dL 6.0 - 8.5
 
Albumin 4.4   g/dL 3.7 -4.7
Globulin, Total 1.9   g/dL 1.5 - 4.5
A/G Ratio   2.3 H   1.2 - 2.2
Bilirubin, Total 0.4   mg/dL 0.0 - 1.2
Alkaline Phosphatase 101   IU/L 44 - 121
AST(SGOT) 16   IU/L 0 - 40
ALT(SGPT) 13   IU/L 0 - 44
 
Lipid Panel        
Cholesterol, Total   242 H mg/dL 100 - 199
Triglycerides 62   mg/dL 0 - 149
HDL Cholesterol 112   mg/dL >39
VLDL Cholesterol Cal 10   mg/dL 5 - 40
LDL Chol Calc (NIH)   120 H mg/dL 0 - 99
 
PSA Total +% Free        
Prostate Specific Ag 1.2   ng/mL 0.0 - 4.0
  Roche ECLIA methodology.
According to the American Urological Associationk Serum PSA should decrrease and remain at undetectable levels after radical prostatectom. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subseqauent confirmatory PSA value 0.2 ng/mL or greater.
Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
PSA, Free 0.39   ng/mL  
  Roche ECLTA methodology.
% Free PSA 32.5   %  
The table below lists the probability of prostate cancer for men with non-suspicious DRE results and total PSA between 4 and 10 ng/mL, by patient age (Catalona et al, JAJMA 1998, 279:1542).
% Free PSA 50 - 64 yr 65 - 75 yr
0.00 - 10.00% 56% 55%
10.01 - 15.00% 24% 35%
15.01 - 20.00% 17% 23%
20.01 - 25.00% 10% 20%
>25.00% 5% 9%
Please note: Caatalona et al did not make specific recommenda6tioons regarding the use of percent free PSA for any other population of men.   Hemoglobin A1c 5.6   % 4.8 - 5.6   Prediabetes: 5.7 - 6.4
Diabetes: >6.4
Glycemic control for adults with diabetes:<7.0       TSH 2.820   uIU/mL 0.450 - 4.500 Iodine, Serum or Plasma 47.5   ug/L 40.0 - 92.0 Vitamin D, 25-Hydroxy 60.5   ng/mL 30.0 - 100.0 SARS-CoV-2, Nucleocapsid         SARS-CoV-2, Nucleocapsid Negative     Negative   This sample does not conain detectable SAR-CoV-2 antibodies. This negative result does not rule out SARS-CoV-2 infection. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. Serologic results should not be used as the sole basis to diagnose or exclude recent SARS-Co/v-2 infection. This assay will not dtect antibodies induced by the currently available SARS-CoV-2 vaccines. The current vaccines elicit antibodies specific to the viral spike protein. Labcorp offers two test codes that detect viral spike-specific antibodiews: 164090 SARS-CoV-2 Semi-Quantitative Total Antibody, Spike and 164055 SARS-CoV-2 Antibody, IgG, Spike (qualitiative). Positive results with this SARS=CoV-2 Antibodies, Nucleocapsid assay suggest recent or previous natural infection with SARS-CoV-2.